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Abstract
Background: Arterial hypertension is a major risk factor for cardiovascular disease and leads to target organ
damage including stroke, heart failure, and kidney disease. About 1.5 billion people worldwide have hypertension,
and it is estimated that it causes about 8 million deaths each year. Although there are several drugs available to
lower blood pressure (BP), a great proportion of treated patients does not reach recommended treatment targets.
Typical antihypertensive drugs target the vessels, the kidneys, and the heart. However, our gut microbiota also
influences cardiovascular health, and gut dysbiosis is associated with hypertension. In this study protocol, we
investigate the potential BP-lowering effect of a probiotic in patients with grade 1 hypertension.
Methods: This study is an exploratory, randomized, double-blind, placebo-controlled, parallel-group study. One
hundred ten patients with grade 1 hypertension (treated or untreated) will be randomized to either the probiotic
Vivomixx® or placebo. The primary endpoint is the nocturnal systolic BP measured by ambulatory blood pressure
monitoring after 8 weeks adjusted for the baseline value. The secondary endpoints are changes from baseline in
nocturnal diastolic BP, antihypertensive medication, fecal microbiome composition, fecal and serum metabolome,
immune cell phenotypes, glucose variability after three standardized breakfasts, and health-related quality of life
(PROMIS-29). We also assess the safety profile of the intervention.
Discussion: We postulate that various administrated bacteria (Lactobacilli, Bifidobacteria, and Streptococcus
thermophilus) convert dietary components into active metabolites that positively affect immune cell function. A
reduction of pro-inflammatory immune cell function could promote a BP-lowering effect.
Trial registration: ClinicalTrials.gov NCT03906578. Registered on 08 April 2019
Keywords: Hypertension, Probiotic, Vivomixx®, Blood pressure, Microbiome, Metabolome, Immune cell phenotype,
Glucose variability, Randomized controlled trial
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Introduction
Arterial hypertension is one of the major risk factors for
cardiovascular disease, including ischemic heart disease,
heart failure, kidney disease, and stroke. About 1.5
billion people worldwide develop arterial hypertension
[1] to which about 8 million premature deaths per
year are attributable [2]. The Global Burden of Dis-
ease Study 2013 revealed that—after dietary risks—
high systolic blood pressure (BP) was the second most
important risk factor for morbidity and mortality glo-
bally, exceeding the risks of tobacco smoke, high body
mass index, high fasting plasma glucose, and high
total cholesterol [3]. In 2017, 15% of women and 25%
of men in Germany had elevated BP [4].
Commonly used antihypertensive drugs typically target
different hormone systems (e.g., renin-angiotensin sys-
tem) and the production of endogenous vasoactive sub-
stances, aiming to protect the blood vessels, heart, and
kidney. However, despite the fact that there are several
drugs available to lower BP, a large proportion of treated
patients do not reach the BP targets recommended by
current guidelines [5]. Non-pharmacological approaches
to prevent and treat hypertension are lifestyle modifica-
tions, such as increased physical activity, reduced salt
and alcohol intake, weight loss, and a healthy diet [6].
Another non-pharmacological approach to lower BP is
the use of probiotics. Research efforts in this field first fo-
cused on milk fermented with Lactobacillus helveticus,
which contains two tripeptides that inhibit the angiotensin-
converting enzyme [7]. Since 1996, a number of clinical
studies that investigated the BP-lowering effects of fermen-
ted dairy products in hypertensive subjects were published,
and the majority of them showed BP-lowering effects.
However, a Cochrane review in 2012 evaluated these
studies and concluded that the effect on systolic BP
was too modest to recommend a general use in the
treatment of hypertension [8]. Two years later, a
meta-analysis of 9 studies, which investigated the ef-
fect of various probiotics, found a modest but clinic-
ally meaningful BP reduction [9]. This was confirmed
by a very recent meta-analysis of 14 studies published
between 2002 and 2019 [10].
Here, we use a probiotic formulation with a high con-
centration of eight different live bacterial strains. Our
proposed mode of action is not through angiotensin-
converting enzyme inhibition but through the modula-
tion of the microbiota-immune interaction. The gut
microbiota is thought to be relevant for cardiovascular
health [11], and microbial imbalance is linked to ex-
perimental and human hypertension [12, 13]. This is
supported by recent epidemiological evidence showing
that higher total yogurt intake lowers the risk of inci-
dent high BP in middle-aged and older adults [14]. Fur-
thermore, hypertensive subjects with a high yogurt
intake had a lower risk of developing cardiovascular
disease [15].
Microbial metabolites are resorbed from the intestinal
lumen and affect various functions of the host. Their ef-
fects are not restricted to the intestine but also affect the
immune system, the vasculature, and the kidney. Hyper-
tensive organ damage seems to be largely mediated by
immune cells like effector memory T cells [16] and T
cells producing interleukin-17 (Th17 cells) [17]. Re-
cently, we demonstrated that a high-salt diet affected
fecal Lactobacillus abundance in mice and humans
alongside increased BP and Th17 abundance. A pro-
biotic Lactobacillus treatment reduced the salt-induced
increase in BP and Th17 [18]. In an exploratory study,
we found that Vivomixx® prevented a high salt-induced
increase in BP in healthy men (unpublished data,
NCT02971787). In subjects eating a synbiotic yogurt for
90 days, we found that an increased capacity for intes-
tinal short-chain fatty acid production was correlated
with diastolic BP reduction [19].
Here, we present the protocol of a randomized,
double-blind, placebo-controlled study investigating the
effects of a probiotic in patients with grade 1 hyperten-
sion. We hypothesize that the probiotic is superior to
placebo in lowering BP. Secondary endpoints are
changes in antihypertensive medication, fecal micro-
biome composition, fecal and serum metabolome, im-
mune cell phenotypes, glucose variability after three
standardized breakfasts, and health-related quality of life.
Methods
Study design
This is an exploratory, randomized, double-blind, placebo-
controlled, parallel-group study conducted at the Experi-
mental and Clinical Research Center of Charité - Universi-
tätsmedizin Berlin, Germany. Recruitment started in
August 2019 (ClinicalTrials.gov identifier: NCT03906578).
Patients are recruited from greater Berlin, Germany. Re-
cruitment is performed via the hypertension outpatient
clinic at Helios Klinikum Berlin-Buch, study flyers in med-
ical practices, and advertisements in a broad range of media
relevant to the study population. We intend to randomize
110 patients with grade 1 hypertension to either 8 weeks of
Vivomixx® or placebo. The intervention is followed by a 4-
week recovery period.
This study protocol was approved by the institutional
review board of Charité - Universitätsmedizin Berlin,
and we obtain written informed consent from all partici-
pants before study entry (Additional files 1 and 2). The
study is conducted in accordance with the Declaration
of Helsinki in its currently applicable version, the guide-
lines of the International Conference on Harmonization
of Good Clinical Practice (ICH-GCP), and applicable
German laws.
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Participants
Information and informed consent forms have been pre-
pared in accordance with the guidelines of the institu-
tional review board of Charité - Universitätsmedizin
Berlin. Potential participants receive both forms at least
1 day before their screening visit. During this visit, a
study physician explains all study procedures, and writ-
ten informed consent is only given after participants had
adequate time to ask questions. We include men and
postmenopausal women with grade 1 hypertension in
this study.
Complete list of inclusion criteria
 Men and postmenopausal women (ratio 1:1)
 50–75 years of age
 Grade 1 hypertension, defined as resting office blood
pressure of 140–159 and/or 90–99 mmHg according
to the European Societies of Cardiology and
Hypertension (ESC/ESH) guidelines [20]
 Hypertension can be treated or untreated
 Body mass index between 18.5 and 34.9 kg/m2
Complete list of exclusion criteria
 Secondary causes of hypertension
 Known target organ damage
 Pharmacological BP treatment which has been
initiated recently (< 1 month) and is still in the
optimization phase
 Ten-year cardiovascular risk score > 5% according to
the 2017 ACC/AHA guideline
 Clinically relevant metabolic, autoimmune, chronic,
progressive, or malignant diseases
 Postoperative phase
 Current or chronic infections
 Use of antibiotics within 3 months before the study
 Regular use of probiotics and dietary supplements
 Special diet for medical reasons
 Food intolerances and food allergies
 Vegan diet
 Weight loss diet or loss of more than 2 kg within 1
month before the study
 Inability to fully understand the significance,
procedures, and scope of this study
 Known alcohol or drug abuse
 Participation in another interventional study
The discontinuation criteria are withdrawal of consent,
subsequent occurrence of an exclusion criterion (e.g.,
change of BP medication), lack of compliance, and other
medical reasons for stopping the intervention.
An advantage in terms of compliance is the fact that
patients only have to take a single dose of the probiotic
or placebo for a relatively short period. A potential dis-
advantage is the fact that they only suffer from a mild
form of hypertension, which might decrease compliance.
To improve and/or ensure compliance, we ask patients
before inclusion if they intend to be compliant, establish
a good relationship, give simple and precise verbal and
written instructions, and directly question patients for
regular probiotics/placebo intake and estimate compli-
ance by counting unused sachets. These efforts also im-
prove the retention of patients in the study. In addition,
we will detect probiotic bacterial strains in stool samples.
However, these bacteria are thought to transiently
colonize the intestine. Thus, their detection in stool
samples after 8 weeks of intervention does not necessar-
ily confirm rigorous compliance.
Randomization
Eligible patients are included after the successful screen-
ing. Randomization is done by the supplier (see below)
based on the lists generated with an ad hoc SAS® pro-
gram (sex stratification, randomly varying block sizes).
Based on these lists, the supplier delivers sequentially
numbered boxes containing sachets to the study center
without any information on group allocation. Thus,
strictly concealed allocation and complete blinding are
ensured. A person of trust from the study center not in-
volved in the study has access to sealed envelopes for
each participant, thereby enabling disclosure of group al-
location if necessary.
Probiotic intervention
Vivomixx® is a microbiotic food supplement. It contains
eight strains of live bacteria (Lactobacilli paracasei,
plantarum, acidophilus, and delbrueckii; Bifidobacteria
longum, infantis, and breve; Streptococcus thermophilus)
in a concentration of 450 billion bacteria per sachet. Pa-
tients take the content of two sachets dissolved in water
in the evening (approx. every 24 h, either 30 min before
or 2 h after dinner). Two sachets yield a daily dose of
9 × 1011 colony-forming units (CFU). The placebo group
takes sachets with an identically appearing powder with-
out any bacteria. Both interventional products are pro-
vided by the supplier Mendes S. A, Lugano, Switzerland.
Adverse events
Vivomixx® has been safely used in other studies and was
well tolerated, even in patients with irritable bowel syn-
drome [21]. Minor adverse events of probiotics can be
increased gas, bloating, and stool frequency. These side
effects are mild and transient. Nevertheless, we question
all patients at each visit for related or unrelated health
issues and record all adverse events. Serious adverse
events due to this probiotic are not to be expected.
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Outcome parameters
All outcomes are assessed at three time points—at base-
line, after 8 weeks of intervention, and 4 weeks after dis-
continuation (recovery).
Our primary hypothesis is that a probiotic containing
eight different strains of live bacteria reduces BP in
grade 1 hypertension. Accordingly, our primary endpoint
is the mean nocturnal systolic BP after 8 weeks of pro-
biotic intake compared to placebo and adjusted for the
baseline value. We already used this outcome to attain a
maximally standardized way of BP measurement [18].
Other established outcomes in hypertension research
like office BP and ambulatory 24-h BP will be included
as important secondary outcomes.
Further secondary endpoints are change of antihyper-
tensive medication, fecal microbiome composition, fecal
and serum metabolome, immune cell phenotypes, glu-
cose variability after three standardized breakfasts and
health-related quality of life from baseline.
We perform a 4-week follow-up after the intervention,
in which procedures will be repeated to investigate any
prolonged treatment effects. We will also control for BP-
reducing lifestyle factors such as weight reduction (an-
thropometry) and dietary habits including salt intake
(food records) before and after the intervention.
Body composition is measured by air-displacement
plethysmography, and the blood is sampled for routine
and research measurements as well as peripheral blood
mononuclear cell (PBMC) isolation. In addition, patients
rate their health-related quality of life with the PROMIS-
29 questionnaire.
Glucose variability is measured by continuous glucose
monitoring (FreeStyle Libre Pro, Abbott). For this, a sen-
sor is placed in the adipose tissue (triceps region) where it
measures the interstitial glucose concentration every 15
min for 7 days. To study possible changes in postprandial
glucose concentrations, patients are asked to eat three
standardized breakfasts on three consecutive mornings
while wearing the sensor. These breakfasts are prepared in
the study center and handed out to patients to eat at
home. Breakfasts are similar in calorie and carbohydrate
content but differ in glycemic index (high, medium, low).
To evaluate and control for dietary intake, patients
record food and beverage consumption in 4-day food re-
cords while wearing the sensor. Although food records
over the whole 7 days might have been preferable, 4-day
records are considered to yield sufficient results, are less
demanding on patients and investigators, and reduce the
time in which dietary habits might change due to re-
cording, e.g., undereating. Records will be analyzed for
macro- and micronutrient content using OptiDiet Plus
(V6.0, GOE, Linden, Germany). This professional ana-
lysis software uses the nutrient content of 12,000 foods
provided by the German Nutrient Database.
From stool samples, bacterial DNA will be sequenced,
and fecal and serum metabolites will be measured by
mass spectrometry. We will explore metabolites with –
omics-based methods. We hypothesize that changes in
the gut microbiota affect the ratio of certain tryptophan
metabolites and levels of short-chain fatty acids, which
in turn affect immune responses and blood pressure.
However, we will also design more experiments that ad-
dress the biological question of this study. The obtained
results will enable the construction of rigorous scientific
hypotheses which can be tested later using -omic or
non-omic methods.
Table 1 provides a detailed overview of assessments
and endpoints.
Power calculation
Based on the above mentioned meta-analysis [9] and on
our own unpublished data (NCT02509962,
NCT02971787), we estimate a mean decrease in systolic
BP of 3.8 mmHg with a standard deviation of 5.0 mmHg
in the probiotic group. In addition, we assume that the
placebo group will have the same systolic BP baseline
value and a small decrease in the mean systolic BP of
0.2 mmHg with the same standard deviation. That leads
to a standardized effect size between groups of (3.8 −
0.2)/(√2 × 5.0) ≈ 0.51. The required sample size to find a
significant effect with a power of 0.8 at a two-sided sig-
nificance level of 0.1 is given by 98 patients (49 per
treatment arm, calculated with ADDPLAN, version 6.1).
To account for approximately 10% dropout, the total
number of patients to be recruited is 110 (98/110 ≈ 0.9).
Data management
To protect participant’s confidentiality, only pseudonyms
are used for all data documentation, sample markings,
and communication with third parties (e.g., laboratories,
collaboration partners). Clinical data are collected in
source documents and electronic case report forms (Re-
search Electronic Data Capture database). Database en-
tries are automatically checked for data format and
appropriate range. We do not rely on an additional inde-
pendent monitoring for this is a single-center, explora-
tory study. Due to the minimal risks of the probiotic
intervention, a data monitoring committee is deemed
unnecessary. We will submit modifications to this proto-
col to the institutional review board, participants, and
investigators. After completion of the study, data will be
stored for 10 years and then be deleted.
We do not ask participants for broad consent. Thus,
we will only use data and samples for the hypotheses
stated in this protocol and will not provide them for an-
cillary studies.
After completion of this study, the results will be
expounded to participants, presented on scientific
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conferences, published in peer-reviewed journals, and
circulated to physicians and the medical laity. We will
comply with the official eligibility guidelines for author-
ship for all publications and do not intend to use profes-
sional writers.
Data analysis
A confirmatory analysis will be conducted based on the
intention-to-treat (ITT) population, defined by the ITT
principle. We want to show that the intervention group
is superior to the control, i.e., the mean nocturnal sys-
tolic BP at 8 weeks after the start of treatment adjusted
for the baseline value is lower in the intervention group
than in the control group. An analysis of covariance
(ANCOVA) adjusted for baseline systolic BP values
using group allocation as a factor will be applied. The
global two-sided significance level is 0.1. Missing values
will be replaced using multiple imputation [22].
A sensitivity analysis to the primary efficacy ANCOVA
model will be applied with additional covariates/factors
given by age and sex. Subgroup analysis is planned for
sex. Descriptive methods will be used for the analysis of
all clinical, demographic, and safety parameters, includ-
ing the calculation of appropriate summary measures of
the empirical distribution as well as 95% confidence in-
tervals and calculation of descriptive two-sided p values.
A safety analysis of frequencies and rates of adverse
events will be performed. Additionally, sensitivity ana-
lyses will be conducted for different populations (per-
protocol population, patients with complete cases). In-
terim analyses are not included in our analysis plan. All
analyses will be done using validated statistical software.
Discussion
With this study, we want to close the gap between the
existing epidemiological, experimental, and our own
clinical data in healthy volunteers. We will do this by
thoroughly investigating the effects of a probiotic that
has not been used in hypertensive patients before. How-
ever, we do not only aim at alleviating hypertension, we
will also use state-of-the-art omics systems approaches
to understand the impact of probiotics on the gut micro-
biome, immunome, metabolome, and vascular pheno-
types in these patients. To the best of our knowledge,
Table 1 Schedule of HYPRO study visits
Study visit V0 V1 V2 V3
Time point Screening Baseline Post-intervention Recovery





Medication x x x x
Physical exam x
Smoking status x
Height, weight, waist-to-hip ratio x
Blood pressure, heart rate, ECG x
Blood sample x x x x
Urine sample x x x x
AE/SAE query x x x
Bodyweight and composition (ADP) x x x
Office BP x x x
24-h ABPM x x x
PBMC isolation x x x
Glucose sensor (7 days) x x x
Food record (4 days) x x x
Standardized breakfasts (3 days) x x x
Stool sample x x x
Health-related quality of life (PROMIS-29) x x x
ABPM ambulatory blood pressure monitoring, ADP air-displacement plethysmography, AE adverse event, BP blood pressure, ECG electrocardiogram, PBMC
peripheral blood mononuclear cells, PROMIS Patient-Reported Outcomes Measurement Information System, SAE serious adverse event
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this is the first study that comprehensively investigates
all of these levels in human hypertension.
We hypothesize that targeting the intestinal microbial
community with live bacteria will improve hypertension
along with an improved immune cell homeostasis. This
mode of action could also be effective in treated hyper-
tensive patients who do not reach the desired treatment
targets. An improved immune homeostasis could not
only lead to lower BP but also to better target organ pro-
tection, since immune cells are known to migrate into
target organs thereby promoting organ dysfunction. Fur-
ther, probiotic strains might stably colonize the gut and
might evoke—in contrast to classical pharmacological
therapy—a long-lasting antihypertensive benefit after
discontinuation of treatment. This will be tested in our
follow-up phase. Moreover, probiotics are generally well
tolerated and have little side effects. Thus, compliance in
hypertensive patients, who are skeptical of classical
pharmacotherapy, might be improved.
We include either untreated grade 1 hypertensive pa-
tients in whom pharmacological treatment can be post-
poned for a limited time in favor of lifestyle
modifications or treated patients who are not on goal
despite adequate pharmacotherapy. Included patients
have no clinical signs of target organ damage, serious
concomitant diseases, or secondary causes of hyperten-
sion. From our point of view, these mildly hypertensive
patients would benefit most from a probiotic interven-
tion. Furthermore, according to applicable guidelines, it
is possible to delay the start or change of pharmacother-
apy for the 12-week study duration at this stage of the
disease. This choice will limit the extrapolation of our
results to other hypertension grades, such as patients
with resistant hypertension. However, these patients
have a higher risk for cardiovascular events, and neces-
sary therapeutic changes cannot be postponed.
Interventional considerations were based on a meta-
analysis that suggested an intervention period of ≥ 8
weeks with ≥ 1011 CFU/day of a multi-strain probiotic to
effectively lower BP [9].
We chose nocturnal BP instead of office BP or 24-h
ambulatory BP measurement to achieve a highly stan-
dardized measurement in the patient’s natural environ-
ment. This standardized measurement, which excludes
variations due to physical activity during the day, allows
to conduct this study with a medium sample size.
Although there is a high level of interest among eligible
patients, recruitment turned out to be rather challenging.
This is mainly due to the fact that BP is highly variable
within subjects. About 8 of 10 candidates fail our pre-
screening, because they cannot be classified as grade 1
hypertensive. Recruitment is additionally impeded by
common comorbidities, such as insulin-dependent type 2
diabetes or severe obesity. Nevertheless, due to our
medium sample size, it is important that demographic,
cardiovascular, and metabolic characteristics are well-
defined and as narrow as possible.
All biomaterials, in particular, stool samples, are col-
lected with the highest scientific standards to allow for
high-quality microbiome analyses [23].
In conclusion, probiotic treatment of patients with
grade 1 hypertension has the potential to lower BP. Due
to its innovative mode of action, probiotic treatments
could be considered for prevention, might delay pharma-
cotherapy, and enable dose reduction of antihypertensive
drugs, and thereby contribute to target organ protection
and the reduction of cardiovascular events.
Trial status
This article is based on the study protocol version 1.4 of
2 July 2019. Recruitment started on 28 August 2019 and
will probably continue until March 2022.
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